Campus Neuried, Anna-Sigmund-Str. 5, 82061 Neuried, Germany
Get in touch with us to discuss your project and discover how the Pioneer Antibody Discovery Platform can help identify your new therapeutic candidates.
Speak with a Pioneer Platform Expert
The New
Pioneer Antibody
Discovery Platform
Step into the Future
of Therapeutic Antibody Discovery
The new Pioneer Antibody Discovery Platform features a state-of-the-art phage display human antibody library for biotherapeutic antibody discovery. The highly-curated library is a 1000 times bigger than the normal human immune repertoire and is designed to offer maximum functional diversity and affinity with excellent developability.
The Pioneer Antibody Discovery Platform delivers a greater selection of candidates with diverse binding activity, and hence a significantly improved opportunity to identify a superior therapeutic antibody.
Our Technology
Diversity, Affinity, and Developability
With decades of experience in custom antibody generation, Bio-Rad has now developed an entirely new phage display library called Pioneer. Harnessing SpyTag technology it has been engineered with a proprietary display method, SpyDisplay, to enable the rapid discovery of therapeutic antibody candidates.
The Pioneer Antibody Discovery Platform is an exceptionally large functional, phage display Fab antibody library, containing 2.25 x 1011 unique antibodies, thereby delivering a high and diverse number of unique hits.
The large size of the library delivers diverse lead candidates with sub-nanomolar affinities possible from initial panning’s. Affinity maturation can be used to further optimize promising therapeutic candidates.
The Pioneer Antibody Discovery Platform has been engineered focusing on developability — post-translational modifications and other sequence liabilities have been minimized to achieve best-in-class developable candidates for your target of interest.
The large size of the library delivers diverse lead candidates with sub-nanomolar affinities possible from initial panning’s. Affinity maturation can be used to further optimize promising therapeutic candidates.
The Pioneer Antibody Discovery Platform has been engineered focusing on developability — post-translational modifications and other sequence liabilities have been minimized to achieve best-in-class developable candidates for your target of interest.
An exceptionally large, functional phage display Fab antibody library
SpyDisplay Technology
SpyDisplay is an innovative method of phage display that uses SpyTag technology. SpyDisplay is a very efficient system, well suited for the selection of high-affinity antibodies.
SpyTag, a short peptide of 13 amino acids (aa), reacts spontaneously and specifically with a SpyCatcher protein (113 aa) to form an isopeptide bond.
SpyDisplay uses a phagemid-based expression vector which encodes a SpyTagged Fab and a SpyCatcher-pIII integrated into the E. coli genome. In SpyDisplay, the Fab is covalently displayed via SpyTag/SpyCatcher ligation on the filamentous phage carrying the SpyCatcher fused to the pIII coat protein. As SpyDisplay utilizes a single vector for both selections during phage display and expression of clones after screening, it significantly improves workflow efficiency with a less error prone process.
SpyLock Technology
SpyLock is a cutting-edge approach to expediting bispecific screening. It takes advantage of the autocatalytic reaction between SpyTag and SpyCatcher. The Bio-Rad team has introduced a groundbreaking innovation with a 'lockable' SpyCatcher named SpyLock, which can be reversibly inhibited to prevent unwanted ligation with a SpyTag. The simplicity of SpyLock technology is reflected by its sequential antibody reactions for the generation of a bispecific prototype.
A SpyCatcher-SpyLock dimer, the BiLockCatcher, reacts with the first SpyTagged antibody fragment (A in the figure). Then by “unlocking” the second SpyLock site using a reducing agent, the second SpyTagged antibody fragment (B) can be loaded to produce a bispecific. Bio-Rad has developed a protocol that can be performed in 90 minutes, as well as a high purity protocol, which usually yields >95% bispecific antibody. When paired with the Pioneer Antibody Discovery Platform, SpyLock technology emerges as an ideal solution for swiftly generating bispecific antibodies tailored for high-throughput screening.
Key Features of the Pioneer Antibody Discovery Platform
Fully synthetic, fully human Fab antibody library specifically designed to minimize nonproductive cloning artefacts — 96% of sequences encode functional light and heavy chains.
- New Antibody library with exceptional size and broad functional diversity
- Proprietary SpyDisplay technology for accelerated candidate selection
- Prototyping of therapeutic candidates in a multitude of formats with TrailBlazer technology
- Rapid generation of bispecific antibodies for high throughput screening with SpyLock Technology
- Ownership of candidates
- World-class specialists and scientists offering a tailored service to your needs
The Pioneer Antibody Discovery Services will deliver:
Evaluation material in rapid prototyping format (based on Bio-Rad‘s proprietary TrailBlazer platform) specific to the clients requirements.
The final antibodies are fully mammalian expressed IgGs, functionally characterized with a complete data package and sequence.
Exclusivity and ownership of sequences of antibody deliverables.
Address
Phone
Email